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Abstract
HIV-1 release is mediated through two motifs in the p6 region of Gag, PTAP and LYPXnL, which recruit cellular proteins
Tsg101 and Alix, respectively. The Nucleocapsid region of Gag (NC), which binds the Bro1 domain of Alix, also plays an
important role in HIV-1 release, but the underlying mechanism remains unclear. Here we show that the first 202 residues of
the Bro1 domain (Broi) are sufficient to bind Gag. Broi interferes with HIV-1 release in an NC–dependent manner and arrests
viral budding at the plasma membrane. Similar interrupted budding structures are seen following over-expression of a
fragment containing Bro1 with the adjacent V domain (Bro1-V). Although only Bro1-V contains binding determinants for
CHMP4, both Broi and Bro1-V inhibited release via both the PTAP/Tsg101 and the LYPXnL/Alix pathways, suggesting that
they interfere with a key step in HIV-1 release. Remarkably, we found that over-expression of Bro1 rescued the release of
HIV-1 lacking both L domains. This rescue required the N-terminal region of the NC domain in Gag and the CHMP4 binding
site in Bro1. Interestingly, release defects due to mutations in NC that prevented Bro1 mediated rescue of virus egress were
rescued by providing a link to the ESCRT machinery via Nedd4.2s over-expression. Our data support a model in which NC
cooperates with PTAP in the recruitment of cellular proteins necessary for its L domain activity and binds the Bro1–CHMP4
complex required for LYPXnL–mediated budding.
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Introduction
The human immunodeficiency virus type I (HIV-1) Gag
polyprotein, p55Gag, is the main structural component of viral
particles [1]. It carries four distinct domains: the N-terminal
Matrix (MA), the central capsid (CA), the Nucleocapsid (NC) and
the C-terminal p6 region. MA is responsible for targeting Gag to
the plasma membrane for assembly via a bipartite signal composed
of a myristic acid moiety and a cluster of basic residues [2,3,4].
The CA domain bears regions essential for Gag-Gag multi-
merization and is the main constituent of the viral core [5,6]. The
NC domain promotes Gag-Gag assembly via its ability to interact
with RNA [7,8,9]. Viral particle budding from the plasma
membrane requires the activity of L domain motifs within p6
[10,11], which recruit cellular proteins necessary for membrane
fission and release [12,13,14,15].
Two late domains have been identified within the p6 of HIV-1
Gag, the PTAP and LYPXnL motifs. The PTAP motif binds the
cellular protein Tsg101 [16,17,18] whereas the LYPXnL motif is
the docking site for Alix/AIP-1 [19,20,21]. Tsg101 functions in
HIV-1 budding [16,22,23] as a member of the Endosomal Sorting
Complex Required for Transport-1 (ESCRT-I) [21,24,25], which
initiates the sorting of surface proteins into late endosomal
compartments known as multivesicular bodies (MVB) [26,27,28].
This process is topologically similar to HIV-1 budding and
requires the recruitment of ESCRT-III members called the
charged-multivesicular body proteins (CHMP) [19,20,21,29] and
the activity of VPS4 AAA-type ATPase [21,30,31,32,33,34]. The
PTAP/Tsg101 driven pathway is considered to be the predom-
inant mechanism for HIV-1 release.
The second L domain motif, LYPXnL, binds Alix
[19,20,21,35,36,37], an ALG-2 interacting host protein [38,39]
presumed to function in endosomal metabolism [40,41,42]. Struc-
tural studies revealed that Alix is comprised of three distinct domains,
an N-terminal Bro1 domain, a LYPXnL binding coiled-coil V
domain, and a C-terminal proline rich domain (PRD), which interacts
with several cellular factors including Tsg101 [19,41,43,44,45]. The
N-terminal Bro1 domain binds the ESCRT-III CHMP4 proteins
[44,46,47]. The banana shaped structure of the Bro1 domain [44,46]
suggests a possible role in membrane curvature [48] during the
normal function of Alix in both MVB and retroviral budding.
Although Alix is currently considered to play a supporting role in
HIV-1 release, it was recently shown to facilitate HIV-1 release in
absence of the PTAP motif [44,47]. Furthermore, Alixis sufficient for
release of Equine Infectious Anemia Virus (EIAV), which contains
only the LYPXnL type L domain motif [20,44,47,49].
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either indirectly, through the Tsg101-PTAP motif interaction, or
directly by the V domain of Alix binding to the LYPXnL motif
[19,20,21]. Recent studies showed that recruitment of CHMP4
proteins by Bro1 is required for Alix function in HIV-1 release
[44,47]. Most recently, it was shown that CHMP4 proteins self-
associate into filaments that promote membrane bending away
from the cytoplasm [50]. Interestingly, over-expression of
dominant negative versions of CHMP proteins induces Class E-
like phenotypes and inhibits HIV-1 budding [19,20,21,51,52,53].
These studies are consistent with a role for ESCRT-III members,
especially the CHMP4b isoform, in facilitating fission events that
lead to HIV-1 separation from the plasma membrane.
In recent years, multiple studies have suggested that the ability
of L domain motifs to facilitate budding and release is context-
dependent [35,54,55,56,57]. This implies that they cooperate with
other regions within Gag to achieve efficient viral release
[35,55,56,57,58,59]. Consistent with this notion, the PTAP motif
was shown to cooperate with the NC-p1 regions [57] and also to
require p6 residues 15–51, which include the Alix binding site, to
function optimally [55]. Most recently, the NC domain of Gag
(hereafter also called NC) was found to engage the Bro1 domain of
Alix, an interaction that is required for the LYPXnL/Alix pathway
to function in HIV-1 release [60]. Mutations within the NC
domain or deletion of the entire domain significantly reduce the
release of HIV-1 particles even though the NC-deleted Gag retains
the ability to assemble particles [56,61,62,63,64]. Together these
observations suggest a role for the NC domain in HIV-1 budding
driven by L domain motifs located within the neighboring p6
domain. The temporal and spatial involvement of NC in particle
budding and egress, and the extent to which it functions with p6
have not yet been clearly established.
The absence of direct evidence for an NC role in HIV-1
budding, and of effective means of interfering with such a function,
make it difficult to establish a functional link between p6 Late
domain motifs and NC. We used Alix to examine a possible role
for NC in HIV-1 budding and identified a small fragment of Bro1
that inhibits both Tsg101/PTAP and Alix/LYPXnL budding
pathways in an NC-dependent manner. Over-expression of the
full length Bro1 domain rescues budding defects caused by
disruption of the PTAP and LYPXnL motifs; rescue requires a
CHMP4 binding site in Bro1 and an intact NC. Mutations in NC
that prevent Bro1-mediated viral release also inhibit the release of
a PTAP-dependent HIV-1 suggesting that NC function is required
for both pathways. Interestingly, mutants defective due to
mutations in NC can be rescued by providing a link to ESCRT
components via a parallel pathway. Collectively, our results
support a model in which NC cooperates with the PTAP and
LYPXnL motifs in p6 to recruit components of the cellular
machinery necessary for HIV-1 budding.
Results
Over-expression of Alix inhibits HIV-1 budding
HIV-1 recruits Tsg101 and Alix to bud from the plasma
membrane of infected cells. When the Tsg101-driven pathway is
not available (HIV-1 PTAP- mutant), over-expression of Alix has
been shown to rescue HIV-1 release defects [44,47]. Titration
analysis indicated that the optimal amount of HA-Alix that
stimulated HIV-1 PTAP- was relatively low (Figure S1A, lane 3),
whereas in contrast, higher amounts failed to rescue release
(Figure S1A, lane 5). Interestingly, amounts of HA-Alix that
prevented the rescue of HIV-1 PTAP- release also caused a
significant decrease in wt HIV-1 release (Figure S1A, lane 9).
Further analysis and quantification of this inhibition, shown in
Figure 1, demonstrated that over-expression of increasing amounts
of HA-Alix potently inhibited HIV-1 exit, as only ,15% of virus
was detected outside the cell (Figure 1B and 1C). Similar results
were obtained when this experiment was performed with the HIV-
1 strain BH10 (data not shown). Alix over-expression also
decreased Gag processing as a modest accumulation of p25CA
and other Gag intermediate processing products was seen
(Figure 1B).
Next, we used transmission electron microscopy (TEM) to
visually examine the defect in HIV-1 release caused by over-
expression of Alix. HIV-1 was blocked at the plasma membrane
where numerous arrested budding structures decorated the cell
surface (Figure 1D). Over-expression of Alix arrested HIV-1
budding at various stages but most structures were arrested at early
and mid-stages of budding (inset a). We also found aberrant and
multi-budded particles (insets b and c) as well as some structures
stopped in the late steps of budding (inset c). Similar results were
observed with the HIV-1 BH10 strain (Figure S1B). These data
suggested that over-expression of Alix led to interference with
HIV-1 morphogenesis and budding. Interestingly, although
PTAP/Tsg101 is considered to be the primary pathway utilized
by HIV-1, over-expression of Alix efficiently decreased HIV-1
release suggesting that the inhibition is due to interference with the
function and/or recruitment of a cellular factor common to both
the PTAP/Tsg101 and LYPXnL/Alix budding pathways.
Over-expression of an N-terminal fragment of Bro1
inhibits HIV-1 release
We tested fragments of the Alix protein to determine the role of
the various domains in the inhibition the protein exerted on HIV-
1 release. We first removed the C-terminal PRD to exclude the
involvement of the numerous cellular partners known to bind this
region, including Tsg101. We then focused on fragments
containing the N-terminal Bro1 and the central V domain
(Figure 2A) because these domains bind ESCRT-III and Gag,
respectively, and were shown to play key roles in Alix function
during virus release [44,47,60,65]. Over-expression of Bro1-V
efficiently inhibited HIV-1 release but had no detectable effect on
Author Summary
Human immunodeficiency virus type 1 (HIV-1) assembles
its structural protein Gag into a viral shell at the plasma
membrane. Gag is divided into several regions, each with
its own distinct function(s). Within the p6 region of Gag,
there are two short peptide sequences, called Late (L)
domains, that serve to recruit cellular proteins Tsg101 and
Alix. In an uninfected cell, these proteins facilitate
membrane dynamics during vesicle budding into cellular
compartments called endosomes. Upon infection, HIV-1
hijacks these proteins and makes use of the machinery to
facilitate viral budding at the plasma membrane. Our study
shows that, in addition to binding the p6 region, Alix also
interacts with the Nucleocapsid (NC) region of Gag.
Importantly, we show that when HIV-1 buds via the Alix-
driven pathway, this interaction with NC is essential for
recruiting host proteins necessary for HIV-1 release.
Moreover, we show that a non-functional fragment of Alix
inhibits Tsg101-mediated HIV-1 release in ways similar to
those caused by mutations in the NC domain of Gag.
Collectively, our findings favor a model in which the p6-
located L domain motifs require cooperation with NC to
facilitate HIV-1 release.
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terminal half of the Bro1 domain reversed the inhibitory effect of
the Bro1-V fragment (Figure 2B), implying that binding via the V
domain is not sufficient for inhibition in this context. To examine
whether the V domain binding to Gag is involved in the Bro1-V
block of HIV-1, we next tested the effect of the Bro1-VF676D
mutant that no longer binds the LYPXnL motif. We found that
Bro1-VF676D retained potent inhibition of HIV-1 release
(Figure 2C), indicating that the Gag binding site in the V domain
is dispensable for interference with viral exit in this context and
suggesting that Bro1-V blocked HIV-1 production via regions
located within the Bro1 domain. To map these inhibitory regions,
we over-expressed the entire Bro1 domain and found that
surprisingly, it had no inhibitory effect on HIV-1. In contrast,
expression of a shorter fragment encompassing the first 202
residues of the Bro1 domain (Broi) caused a potent inhibition of
HIV-1 release (Figure 2D). Broi had little effect on Gag
accumulation in the cell (Figure 2D). These findings identify the
N-terminal 202 residues of the Bro1 domain as the region that
drives inhibition of HIV-1 release (Figure 2E).
Broi inhibits both the PTAP/Tsg101 and LYPXnL/Alix
budding pathways
To further examine the nature of the inhibition caused by the
dominant negative fragments on HIV-1 release, we over-expressed
Broi and Bro1-V with an HIV-1 lacking the LYPXnL motif
Figure 1. Over-expression of Alix inhibits HIV-1 release. (A) Schematic representation of the domain organization of Alix. Bro1: BCK1-like
resistance to osmotic shock 1, V: V-shaped domain, PRD: Proline Rich Domain. Numbers indicate positions of amino acid residues. (B) Virus-release
assay showing that over-expression of Alix inhibits virus release. 293T cells were transfected with either wild-type (wt) pNL4-3 plasmid alone or with
increasing amounts of HA-Alix. Pelleted virions and cell lysates were analyzed by SDS-PAGE and western blot using the indicated antibodies. Gag
intermediate products are indicated with (*) symbols. (C) Relative release efficiency of HIV-1 virions upon over-expression of Alix. The release
efficiency in presence of Alix (calculated at the highest amount shown in B, lane 4) is relative to the release efficiency of NL4-3 alone, which was
arbitrarily set at 100. Error bars indicate the standard deviation from four separate experiments. (D) Transmission Electron Microscopy (TEM) images of
thin-sectioned 293T cells transfected with pNL4-3 wt alone (upper left panel) or pNL4-3 wt + Alix (lower left panel and close-ups of regions of interest
a, b, c) showing arrested budding particles.
doi:10.1371/journal.ppat.1000339.g001
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HIV-1 relies only on the PTAP/Tsg101 pathway for viral exit. As
with wild type pNL4-3, over-expression of delBroV had no effect
on the release of NL4-3 YP- (Figure 3A). In contrast, over-
expression of the Bro1-V inhibited NL4-3 YP- virus release and
Broi exerted the most potent inhibition (Figure 3A). This indicated
that over-expression of Broi (and Bro1-V) disrupted a key function
in the PTAP/Tsg101 budding pathway.
To examine the effect of Broi and Bro1-V on HIV-1 release
driven via the LYPXnL/Alix pathway, we used the budding
defective HIV-1 PTAP- mutant. Over-expression of Alix has been
shown to rescue the release of this mutant virus by acting through
the LYPXnL motif [44,47]. We reasoned that if the NC-Bro1
interaction is involved in the Alix-driven pathway as was recently
suggested [60], Broi and Bro1-V might act as dominant negative
fragments and interfere with the ability of Alix to rescue the
PTAP- mutant. We tested this hypothesis by over-expressing Alix
alone or with either fragment and found that in the presence of
Broi or Bro1-V, Alix failed to rescue budding of the defective HIV-
1 PTAP- mutant (Figure 3B, compare lanes 4, 5, and 6). Together
these results indicate that Broi and Bro1-V exert a global
inhibitory effect on HIV-1 budding and release.
The NC domain of HIV-1 Gag is the primary target for Broi
inhibition
The results above indicated that Broi efficiently interfered with
HIV-1 release, prompting the question as to whether Broi interacts
directly with Gag. To examine this, Alix, Bro1, Broi and PRD
were tested for their ability to interact with HIV-1 Gag (Figure 4A,
left panel) and a GagDp6 mutant (right panel) in immunoprecip-
itation assays. In contrast to PRD, Alix, Bro1 and Broi efficiently
pulled-down Gag and the GagDp6 mutant (Figure 4A). This
demonstrated that in the cell, Bro1 binds HIV-1 Gag in a p6-
independent manner and that the Broi region is sufficient for this
interaction. Further examination by in vitro pull-down assays
showed that NC binds the Bro1 domain of Alix (Figure 4B). These
data confirmed that Alix contains a novel binding site for Gag
located within Bro1, which is in agreement with the recent findings
of Popov et al, 2008 [60]. Our results identify the first 202 residues
of the Bro1 domain as sufficient for binding HIV-1 Gag.
Because the new Alix-Gag interaction is mediated via NC [60],
we next examined whether the observed Broi interference with
HIV-1 release occurs through the NC domain of Gag. For this, we
assessed the effect of Broi on an HIV-1 mutant lacking the NC
domain [62]. We used the HIV-1 DelNC/PR- mutant that
Figure 2. The N-terminal region of Bro1 inhibits the release of HIV-1. (A) Schematic representation of constructs used in the experiment.
Numbers indicate positions of amino acid residues. (B, C, D) 293T cells were transfected with either pNL4-3 plasmid alone or with increasing amounts
of the indicated dominant-negative fragments of Alix. Pelleted virions and cell lysates were analyzed by SDS-PAGE and western blot using the
indicated antibodies. (B) Over-expression of Bro1-V but not delBroV inhibited virus-release. (C) The Bro1-VF676D mutant retains inhibitory effect on
HIV-1 release. (D) Broi, but not Bro1, inhibits HIV-1 release. (E) Relative release efficiency of HIV-1 virions upon over-expression of each of the four N-
terminal fragments of Alix. Error bars indicate the standard deviation from three separate experiments.
doi:10.1371/journal.ppat.1000339.g002
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(PR) was inactivated [62]. Over-expression of Broi had little effect
on the release of HIV-1 DelNC/PR- mutant (Figure 4C, left
panel), but retained a potent inhibitory effect on HIV-1 PR- that
carries an intact NC domain (Figure 4C, right panel), implying
that NC is the primary target for Broi inhibition. In support of this
finding, Broi failed to immunoprecipitate the mutant DelNC Gag,
which retained binding to full length Alix (Figure 4D). These
results indicate that Broi inhibition of HIV-1 release is mediated
via NC.
Gag recruitment of Broi to the plasma membrane inhibits
HIV-1 budding
Since Broi interacts with Gag, we examined the cellular
localization of Broi vis-a `-vis HIV-1 Gag. Using confocal microscopy
analysis, we found that Broi displayed a diffuse cytoplasmic
distribution and localized to intracytoplamic vacuoles (Figure 5A).
We next examined the localization of Broi vis-a `-vis HIV-1 Gag in
the cell and found that both proteins displayed a clear colocalization
at the plasma membrane (Figure 5A, lower panels). This result
indicated that HIV-1 Gag recruits Broi to the plasma membrane.
After establishing that HIV-1 Gag and Broi co-immunoprecip-
itated in the cell and colocalized at the plasma membrane, we
sought to visualize the effect of Broi on HIV-1 morphogenesis and
release from the cell using TEM. The over-expression of Broi led
to the accumulation of multiple arrested budding structures at the
plasma membrane (Figure 5B, a and b). We captured numerous
crescent shaped particles, emerging outward to bud from the
cytoplasm and aberrant, multi-budded structures that were
tethered to the cell surface (Figure 5C and Figure S2A). The
arrested budding particles appeared similar to those observed
following the over-expression of a dominant negative version of
Tsg101 [23] or Alix [65]. These findings demonstrate that Broi
over-expression potently inhibits HIV-1 budding.
Over-expression of Broi causes the formation of Class E
compartments
Broi over-expression exerted a potent inhibition on HIV-1
budding via the NC domain in Gag. This suggested that Broi
binding interfered with p6 recruitment of one or multiple members
of the ESCRT machinery that function in HIV-1 budding and
release. Since HIV-1 release and MVB inward budding both
require the recruitment of members of the same machinery for
membrane fission, we asked whether Broi is recruited to endosomal
compartments and interferes with MVB vesicle formation. Broi
displayed a diffuse cytoplasmic staining (Figure 5 and Figure 6). In
addition, Broi also accumulated in large intracytoplamic vacuoles
reminiscent of enlarged endosomal vacuoles (Figure 6A). Interest-
ingly, Broi associated with the membrane of these vacuoles
(Figure 6A, inset). To check whether these intracytoplasmic
vacuoles were aberrant Class E compartments, we examined Broi
localization in presence of the AAA-type ATPase VPS4a, which is a
key player in MVB function. Broi affected the intracellular
distribution of VPS 4a protein and caused it to accumulate in the
enlarged endosomal compartments (Figure 6A, lower panels). This
result indicates that Broi over-expression caused the formation of
class E compartments. To examine whether Broi-mediated
inhibition is specific to HIV-1 and not due to a general toxicity
that adversely affected the cell, we tested the impact of Broi and Alix
over-expression on the release of the Moloney Murine Leukemia
Virus (MoMLV), a gammaretrovirus that requires ESCRT proteins
but not Tsg101 for viral egress [16]. Expression of increasing
amounts of Broi (comparable to those used in Figure 2) or Alix had
no effect on the release of MoMLV (Figure 6B), demonstrating that
the effect of Broi on HIV-1 release is specific.
The Bro1 domain of Alix binds CHMP4 isoforms, the ESCRT-
III components that have been shown to be essential for HIV-1
budding and release [44,47]. We hypothesized that Broi might
have interfered with CHMP4 recruitment to Gag by titration of
Figure 3. Broi and Bro1-V inhibit HIV-1 release mediated via both Tsg101 and Alix pathways. (A) Inhibition of an HIV-1 mutant lacking the
LYPXnL motif. 293T cells were transfected with either pNL4-3 mutant lacking the LYPXnL motif (pNL4-3 YP-) alone or with the indicated dominant-
negative fragment of Alix. Pelleted virions and cell lysates were analyzed by western blot using the indicated antibodies. (B) Interference with Alix
driven rescue of an HIV-1 mutant lacking the PTAP motif. 293T cells were transfected with either wt pNL4-3 alone, with pNL4-3 mutant lacking the
PTAP motif (pNL4-3 PTAP-) alone or with Alix in the presence or absence of the indicated dominant-negative fragment of Alix. Pelleted virions and
cell lysates were analyzed by SDS-PAGE and western blot using the indicated antibodies.
doi:10.1371/journal.ppat.1000339.g003
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this hypothesis, we examined the ability of Broi to bind the three
isoforms of CHMP4 using immunoprecipitation assays. Although
Broi carries part of the CHMP4 binding interface [44,46,47,66], it
was unable to interact with the three CHMP4 isoforms (Figure
S3A, S3B, and S3C), even though it retained binding to MAP/
RabGAPLP, a known cellular partner of the Bro1 domain of Alix
[67] (Figure S3D). The inability of Broi to bind CHMP4 isoforms
was also observed in yeast two hybrid assays (data not shown). We
conclude that Broi interference with HIV-1 budding is not due to
the titration of CHMP4 proteins.
Over-expression of Bro1-V inhibits HIV-1 budding in a
CHMP4–dependent manner
Over-expression of Bro1-V caused inhibition of HIV-1 release.
Moreover, mutation of the Gag binding site in Bro1-V (Bro1-
VF676D) had no effect on the ability of this fragment to inhibit
HIV-1 release, confirming that Bro1-V interference with HIV-1
release is primarily mediated via the Bro1 domain. To address
whether this inhibition is related to Bro1 recruitment of CHMP4,
we constructed Bro1-VI212D, a mutant that has lost the ability to
bind CHMP4 isoforms, and tested its effect on HIV-1 release.
Bro1-VI212D mutant had little to no effect on HIV-1 release
(Figure 7A) indicating that Bro1-V inhibition of HIV-1 production
required an intact CHMP4 binding site in Bro1. Surprisingly,
whereas Bro1-V strongly bound Gag missing the p6 domain,
Bro1-VI212D lost the ability to bind this truncated Gag (Figure 7B),
while retaining binding to full length Gag (data not shown). These
results demonstrated that the mutation of the CHMP4 binding site
in Bro1 affected its ability to bind Gag via NC but not p6 and that
the Bro1-V inhibition of HIV-1 release is due to the binding of
Bro1 to NC and requires an intact CHMP4 binding site.
To visualize the Bro1-V effect on virus release, we examined
HIV-1 release in cells expressing Bro1-V by TEM. This analysis
showed multiple cells carrying a high number of arrested HIV-1
budding structures that decorated the cell surface. Because the
majority of the arrested particles displayed an early budding
phenotype, viral morphogenesis was examined at time 32 and
48 hours post-transfection to evaluate the inhibition caused by
Bro1-V overtime. At both time points, over-expression of Bro1-V
impaired HIV-1 budding, allowing the capture of nascent particles
carrying crescent shaped electron-dense material (Figure 7C).
Arrested budding structures that remained attached to the plasma
membrane and displayed an aberrant morphology were also
observed. Remarkably, at 48 h, some of these structures showed a
‘‘ring-like’’ structure or a filament surrounding the budding neck
of the particles (Figure 7D and Figure S2B), that is reminiscent of
those caused by dominant negative variants of ESCRT proteins
[21]. Together these data indicate that Bro1-V interferes with
Figure 4. The NC domain of HIV-1 Gag is the primary target for Broi inhibition. (A) Broi and HIV-1 Gag co-immunoprecipitate in 293T cell
lysates. 293T cells were co-transfected with either Gag-Pol (left panel) or GagDp6-Pol (right panel) constructs along with expression vectors for HA-
Alix, HA-Bro1, HA-Broi, or HA-PRD. Cells were lysed in RIPA buffer and clear lysates were incubated with anti-HA antibody-conjugated beads. Both
input and immunoprecipitated complexes were ran on SDS-PAGE for western blot analysis using the indicated antibodies. (B) The Bro1 domain of Alix
binds NC in vitro. MBP and MBP-NC proteins were expressed in E.coli, immobilized on amylose resin and incubated with lysates from 293T cells
expressing HA-Bro1. Captured Bro1 was detected with anti-HA antibody and MBP proteins were visualized by Coomassie blue staining. (C) The
release of NL4-3 DelNC/PR- but not NL4-3 PR- is insensitive to the over-expression of Broi. 293T cells were transfected with either pNL4-3 DelNC/PR-
(Left panel) or pNL4-3 PR- (right panel) in presence or absence of HA-Broi. Pelleted virions and cell lysates were analyzed by SDS-PAGE and western
blot using the indicated antibodies. (D) Alix but not Broi co-immunoprecipitated with HIV-1 Gag DelNC. 293T cells were co-transfected with HIV-1 Gag
DelNC/PR- along with either HA-Alix or HA-Broi. Cells were lysed in RIPA buffer and clear lysates were incubated with anti-HA antibody-conjugated
beads. Both input and immunoprecipitated complexes were ran on SDS-PAGE for western blot analysis using the indicated antibodies.
doi:10.1371/journal.ppat.1000339.g004
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and an intact CHMP4 binding site.
The Bro1 domain of Alix links Gag to ESCRT-III members
via NC
Our studies demonstrated that Gag recruited Alix via its Bro1
domain in a p6 independent manner (Figure 4). In addition, we
found that over-expression of Bro1 caused no inhibition of HIV-1
(Figure 2). In fact, expression of higher amounts of Bro1 stimulated
HIV-1 release (See Figure S5D). This suggested that Bro1 binding
to Gag might be sufficient to mediate L domain function.
Consistent with this hypothesis we found that, like Alix, over-
expression of the isolated Bro1 domain rescued the release of the
HIV-1 PTAP- defective mutant (data not shown). This rescue was
Figure 5. Broi is recruited by Gag to the plasma membrane and interferes with HIV-1 budding. (A) First two upper left panels show a cell
expressing HA-Broi (white). The next panel shows a reconstructed 3D view of a stack of Z sections from a cell expressing HA-Broi and Gag-GFP. Lower
panels show a single Z section of the same cell showing colocalization of Broi and Gag-GFP at the plasma membrane. Broi (white) was stained with a
mouse monoclonal anti-HA antibody and an Alexa 633-conjugated anti-mouse antibody. Nuclei were counterstained with DAPI (blue). F-actin was
stained with Alexa 568-conjugated phalloidin (red) to delineate cells. The colocalization channel (yellow) of Broi and Gag-GFP was built using Imaris
software. Scale bar=5 mm. (B, C) Electron micrographs of 293T cells co-transfected with pNL4-3 wt and HA-Broi. (B) Arrested budding structures are
indicated with black arrows. Two regions of interest in (a) and (b) show budding structures carrying electron-dense crescent-shaped material at a
higher magnification. (C) HIV-1 budding structures tethered to the plasma membrane.
doi:10.1371/journal.ppat.1000339.g005
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over-expression rescued the release of an HIV-1 mutant lacking
both PTAP and LYPXnL motifs (NL4-3 PTAP-/YP-) (Figure 8A).
Bro1 over-expression also corrected the typical processing defect
associated with L domain impairment, as seen by further
maturation of p25CA into p24CA product (Figure 8A, see darker
exposure of this panel). In contrast, Alix rescue of the L domain
defective double mutant was nearly undetectable (Figure 8A).
To examine whether the rescue of the HIV-1 double mutant by
Bro1 was mediated via the NC domain in Gag, we performed the
Bro1 rescue assay with either NL4-3 PTAP-/YP- or with NL4-3
PTAP-/YP- lacking NC (DelNC) and carrying an inactive
protease (PR-). We first showed that alterations of PTAP and
LYPXnL motifs in the DelNC/PR- virus ablated release
(Figure 8B, lane 3), demonstrating that this virus requires L
domains to exit the cell. Over-expression of Bro1 failed to rescue
the NL4-3 PTAP-/YP- DelNC/PR- mutant (Figure 8B) indicating
that Bro1-mediated rescue required an intact NC domain in Gag.
To verify whether Bro1 binding to NC recruited CHMP4
proteins, we next tested Bro1I212D, a Bro1 mutant carrying a
disrupted CHMP4 binding site, for its ability to rescue the HIV-1
PTAP-/YP- double mutant. Bro1I212D failed to rescue the release
Figure 6. Over-expression of Broi causes the formation of Class E compartments but has no effect on MoMLV release. (A) The two
upper left panels show a Z section of a cell expressing HA-Broi (white). Inset shows, at a higher magnification, an area of the cell (white rectangle)
where HA-Broi associated with membranes of intracytoplasmic vacuoles. The two upper right panels show a Z section of a cell expressing GFP-VPS4a
(green). Lower panels show Z sections of cells expressing both HA-Broi and GFP-VPS4a. Broi was stained with a mouse monoclonal anti-HA antibody
and an Alexa 633-conjugated anti-mouse antibody. Nuclei were counterstained with DAPI (blue). The colocalization channel (yellow) of Broi and GFP-
VPS4a was built using Imaris software. Scale bar=5 mm. (B) Over-expression of Broi does not inhibit the release of MoMLV. 293T cells were transfected
with either pNCA plasmid alone or with Broi and Alix. Pelleted virions and cell lysates were analyzed by western blot using the indicated antibodies.
doi:10.1371/journal.ppat.1000339.g006
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fragment retained binding to Gag and was found incorporated in
VLPs (Figure 9B and data not shown). These results demonstrate
that Bro1 binding to NC links Gag directly to the CHMP4
proteins, which are required for HIV-1 release. The data also
show that Bro1 alone can facilitate HIV-1 release in the absence of
L domain motifs PTAP and LYPXnL, indicating that the Bro1
domain is the smallest functional unit of Alix.
We found that Alix rescue of the double mutant HIV-1 PTAP-/
Y P -w a sd r a m a t i c a l l yw e a k e ri nc o m p a r i s o nt oB r o 1r e s c u e
(Figure 8A). Therefore, in the context of full length Alix, binding to
Gag via both the Bro1 and V domains is required for its function in
HIV-1 release. The finding that Bro1 bound NC directly (Figure 4B)
and rescued release of the double mutant HIV-1 PTAP-/YP- virus in
an NC-dependent manner (Figure8A and 8B) is strong evidence for a
role of an NC-Bro1 interaction in HIV-1 budding. Bro1 rescue of the
double mutant HIV-1 PTAP-/YP- via NC requires an intact
CHMP4 binding site (Figure 8C) demonstrating that NC is the site
through which a Bro1-CHMP4 complex is recruited by HIV-1 Gag
to release virus via the LYPXnL/Alix pathway.
Figure 7. Over-expression of Bro1-V inhibits HIV-1 budding in a CHMP4–dependent manner. (A) The inhibitory effect of Bro1-V is
dependent on its CHMP4 binding site. 293T cells were transfected with either pNL4-3 plasmid alone or with increasing amounts of the indicated
mutants of Bro1-V. Pelleted virions and cell lysates were analyzed by SDS-PAGE and western blot using the indicated antibodies. (B) Bro1-V but not
Bro1-VI212D co-immunoprecipitates with HIV-1 GagDp6. 293T cells were co-transfected with GagDp6-Pol along with expression vectors for HA-Alix,
HA-Bro1-V, HA-Bro1-VI212D and HA-PRD. Cells were lysed in RIPA buffer and clear lysates were incubated with anti-HA antibody-conjugated beads.
Both input and immunoprecipitated complexes were ran on SDS-PAGE for western blot analysis using the indicated antibodies. (C–D) Electron
micrographs of 293T cells co-transfected with pNL4-3 wt and HA-Bro1-V. (C) The black boxes indicate two regions of interest shown in (a) and (b) at a
greater magnification. (D) HIV-1 arrested budding structures. Arrows indicate the electron-dense ‘‘ring-like’’ structure visible at the budding neck of
arrested particles.
doi:10.1371/journal.ppat.1000339.g007
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HIV-1 PTAP-/YP- mutant
In the cell, other proteins have been described to carry defined
Bro1 domains. To test whether other Bro1-related proteins
function in HIV-1 release in a manner similar to Alix, we selected
HD-PTP, Rhophilin-2 and Brox, three cellular proteins that share
structural similarities with Alix [46,68,69,70]. Although these
proteins carry defined Bro1 domains, only the Bro1 domains of
HD-PTP and Brox bind CHMP4 proteins. In contrast to Alix,
over-expression of HD-PTP, Brox and Rhophilin-2 failed to
rescue the release of the HIV-1 PTAP- mutant (data not shown).
Since the isolated Bro1 domain of Alix was able to efficiently
rescue HIV-1 release in a p6-independent manner and stimulate
HIV-1 release (Figure 8 and Figure S5D), we isolated the Bro1
domains of HD-PTP and Rhophilin-2 (Figure S4) and examined
their ability to functioninHIV-1release.We firsttested whether the
Bro1 domains of HD-PTP and Rhophilin-2, named HDBro1and
RhoBro1 hereafter (Figure S5A), bind Gag. Using immunoprecip-
itation assays (Figure S5B), we found that both domains captured
Gag in mammalian cell extracts. We next examined whether this
binding alone is sufficient to link Gag to the downstream ESCRT-
III machinery and facilitate HIV-1 release. Over-expression of
HDBro1, RhoBro1 or Brox (data not shown) did not rescue the
release of HIV-1 PTAP-/YP- but actually inhibited Gag processing
as little to no p24CA protein was detected in cell extracts (Figure
S5C). These results demonstrate that although the NC domain of
Gag recognizes other cellular Bro1 domains, only the Bro1 domain
of Alix specifically functions in HIV-1 release. The finding that
HDBro1 and Brox (data not shown), which also bind CHMP4b
proteins [68,71], failed to rescue the HIV-1 PTAP-/YP- mutant,
indicates that the Bro1-CHMP4 complex recruited via NC operates
in a context-dependent manner. Thisresult suggests that in addition
to the CHMP4 binding site, other regions within the Bro1 domain
of Alix are necessary for its function in the release of HIV-1 virions
from the cell. Collectively, these data indicate that the rescue of
HIV-1 budding defects by the Bro1 domain of Alix is efficient and
specific.
Mapping of NC regions required for Bro1 function in HIV-
1 release
Recent studies demonstrate that disruption of both zinc fingers
in NC inhibits Alix interaction with Gag and facilitation of virus
release [60]. To map regions in NC involved in the recruitment of
the Bro1 domain of Alix, we used mutations in NC that disrupt
both zinc fingers (Figure 9A). In this experiment, the ability of the
Bro1 domain of Alix to rescue wild type or the zinc finger mutant
(2Zf-) [72,73] lacking both PTAP and LYPXnL L domains was
examined. In contrast to the HIV-1 L domain double mutant (PY-)
carrying a wild type NC, the 2Zf- triple mutant was only weakly
rescued by Bro1 over-expression (Figure 9B), demonstrating that
NC zinc fingers play an important role in Bro1-mediated rescue of
HIV-1 release. However, these mutations reduced but did not
completely prevent Bro1 from rescuing viral release, suggesting that
other regions in NC may be involved in Bro1 recruitment.
To search for additional regions in NC involved in Bro1
recruitment and function in HIV-1 release, we generated HIV-1
constructs carrying mutations of basic residues scattered throughout
NC, because alterations of these residues were previously shown to
affect virus release [61,63,64]. Substitution of seven lysine and
arginine residues in the first (mutant RKI) or the second half of NC
(mutant RKII) to alanines (Figure 9A), combined with alterations of
the PTAP and LYPXnL motifs led to a complete loss of viral release
(Figure 9C). In contrast to RKI mutant however, RKII virus release
was rescued with the over-expression of Bro1 (Figure 9C)
demonstrating that basic residues in the N-terminal half of NC
are required for Bro1 facilitation of HIV-1 release and suggesting
that this region of NC is involved in the recruitment of Bro1.
Mutations of basic residues throughout NC (mutants RKI and
RKII) or in zinc fingers caused a severe decrease in the release of
virions carrying an intact PTAP motif (Figure 9D). For this
experiment, the level of virus release, as well as Gag processing in
the cell, was examined by running protein extracts in conditions
that allow good resolution of the p25/24 CA doublet. The pattern
obtained with NC mutants RKI and RKII was strikingly similar to
that of the PTAP motif mutant virus (PTAP-) (Figure 9D, lanes 3–
Figure 8. The Bro1 domain of Alix links Gag to ESCRT-III via NC. (A) The isolated Bro1 domain, but not the full-length Alix, rescues the release
of the NL4-3 PTAP-/YP- virus. 293T cells were transfected with either pNL4-3 PTAP-/YP- plasmid alone or with HA-Bro1 or HA-Alix. Pelleted virions and
cell lysates were analyzed by SDS-PAGE and western blot using the indicated antibodies. The asterisk indicates a longer exposure showing details of
p24/p25 processing in the cells. (B) The rescue of the NL4-3 PTAP-/YP- double mutant virus depends on an intact NC domain in Gag. HA-Bro1 was co-
expressed in 293T cells with either pNL4-3 DelNC PTAP-/YP-/PR-, which lacks NC (DelNC) and carries an inactive viral protease (PR-) (lane 4) or pNL4-3
PTAP-/YP- (lane 6) as a control. Pelleted virions and cell lysates were analyzed by SDS-PAGE and western blot using the indicated antibodies. (C) The
rescue of NL4-3 PTAP-/YP- release by Bro1 requires an intact CHMP4 binding site. 293T cells were transfected with either pNL4-3 PTAP-/YP- plasmid
alone or with increasing amounts of HA-Bro1 (lanes 3–4) or HA-Bro1I212D mutant (lanes 5–6). Pelleted virions and cell lysates were analyzed by
western blot using the indicated antibodies.
doi:10.1371/journal.ppat.1000339.g008
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PTAP motif is not sufficient to drive virus release, and suggests
that NC and the PTAP motif play cooperative roles in viral
release. The effect of mutations in NC on virus production was
previously attributed to assembly and/or virus budding defects
[61,74]. We hypothesized that NC mutations might interfere with
virus budding by preventing the recruitment of cellular compo-
nents involved in PTAP-mediated HIV-1 release. If this is the case,
we reasoned that release defects caused by mutations in NC should
be alleviated by recruitment, via regions in Gag outside of the NC
domain, of cellular components known to facilitate viral release. In
support of this hypothesis, we found that over-expression of
Nedd4.2s, an isoform of the E3 ubiquitin ligase Nedd4.2 that was
recently shown to stimulate the release of an HIV-1 variant
missing L domains and NC [75,76], efficiently rescued the release
of 2Zf-, RKI, and RKII mutants lacking the PTAP and LYPXnL
motifs (Figure 9E). This result demonstrates that NC plays a key
role in connecting HIV-1 Gag to components of the cellular
budding machinery necessary for HIV-1 release.
Discussion
In this study, we find that the over-expression of Alix causes a
severe reduction of HIV-1 release. Alix-mediated inhibition is
Figure 9. Mapping of regions in NC important for HIV-1 release. (A) Schematic representation of NC residues (1–55) with the two zinc fingers
(Zf). Cysteine residues (C) changed to serine in the 2Zf- mutant are circled whereas arginine and lysine residues (R, K) were substituted to alanine in
RKI (K3 to K26) and RKII (K26 to K52) mutants are underlined. (B, C) Zinc fingers and basic residues in the N-terminal portion of NC are necessary for
the rescue of HIV-1 PTAP-/YP- (here named PY-) release by Bro1. (B) 293T cells were transfected with either pNL4-3 2Zf-, which carries disrupted zinc
fingers (lane 1), or pNL4-3 2Zf-/PY- (lanes 2–3). pNL4-3 PY- is used (lanes 4–5) as a control for Bro1 rescue. In lane 3, co-transfection with pNL4-3 2Zf-/
PY- and HA-Bro1 partially rescues viral release. (C) 293T cells were transfected with either pNL4-3 RKI (lanes 1-3) or pNL4-3 RKII (lanes 4–6) carrying
either wt p6 (lanes 1 and 4) or a (PY-) p6 (lanes 2–3 and 5–6) and HA-Bro1 to examine the ability of Bro1 to rescue viral release. The asterisk indicates a
longer exposure showing p24/p25 doublets in cell extracts. (D, E) Release defect of 2Zf-, RKI, RKII mutants is rescued by over-expression of Nedd4.2s.
(D) 293T cells were transfected either with pNL4-3 (lane 1) or 2Zf-, RKI, RKII, and PTAP- mutant constructs (lanes 2–5). (E) 293T cells were transfected
with either 2Zf-, RKI, RKII (lanes 1, 4 and 7) or their (PY-) mutant counterparts alone (lanes 2, 5, and 8) or with Nedd4.2s (lanes 3, 6, and 9). Pelleted
virions and cell lysates were analyzed by SDS-PAGE and western blot using the indicated antibodies.
doi:10.1371/journal.ppat.1000339.g009
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the V and the PRD domains respectively, suggesting that the Bro1
domain is responsible for this inhibition. These results reveal that
Bro1 contains a novel binding site for Gag, which is in agreement
with data reported by Gottlinger and colleagues [60]. We extend
these observations with multiple findings that support a role for the
Bro1 domain in HIV-1 budding and release. Specifically, we find
that the over-expression of Bro1 rescues the release of an HIV-1
mutant lacking both the PTAP and LYPXnL motifs, and that this
rescue provides the first direct evidence that Gag contains a site
outside of p6 that mediates virus budding. Importantly, Bro1-
driven rescue of HIV-1 release requires the CHMP4 binding site
in Bro1 and an intact NC domain in Gag, demonstrating that NC
is a novel site that links Gag to the cellular machinery required for
HIV-1 release. A dominant negative version of Bro1, Broi,
potently inhibits HIV-1 release driven via either the PTAP/
Tsg101 or the LYPXnL/Alix pathway. Broi mediated inhibition is
NC-dependent and arrests HIV-1 budding at the plasma
membrane. Interestingly, mutations in NC that prevent the
Bro1-mediated rescue of an HIV-1 lacking both p6-L domains
also decrease HIV-1 particle production. Moreover, release defects
caused by mutations in NC are corrected by linking HIV-1 to the
host budding apparatus via over-expression of Nedd4.2s, a cellular
protein that was recently described to link Gag to the ESCRT
machinery via interactions outside of the NC and p6 domains.
Our studies indicate that NC plays a pivotal role in p6-mediated
Late domain functions by controlling the recruitment of the host
budding machinery that is necessary for HIV-1 egress.
The role of NC in the LYPXnL/Alix budding pathway
A role for NC in HIV-1 budding driven via the LYPXnL/Alix
pathway has been recently reported [60]. This new function
requires residues in NC believed to interact with the Bro1 domain
of Alix. Consistent with this notion, Bro1 is sufficient to rescue the
release of an HIV-1 mutant lacking only the PTAP motif or both
PTAP and LYPXnL motifs. Because this rescue requires a
CHMP4 binding site in Bro1, the results clearly show that Bro1
links Gag to members of ESCRT-III via an interaction with NC,
thus identifying Bro1 as the smallest functional unit of Alix. These
findings show that, in addition to its known Gag binding site in the
V domain, Alix contains a second binding site for Gag located
within Bro1 that mediates the recruitment of CHMP4 proteins
necessary for HIV-1 separation from the plasma membrane.
In contrast to Bro1, Alix does not efficiently rescue the defective
HIV-1 double mutant PTAP-/YP- even though it retains binding
to the Gag mutant lacking p6 through the Bro1 domain.
Therefore, when expressed in the context of Alix, the Bro1
domain is not sufficient, or not available, to function when the V
domain is not bound to the LYPXnL motif, possibly because the V
and PRD domains may be masking the functional site within
Bro1. Since removal of the V and PRD domains generates a
functional Bro1 domain, it is conceivable that the binding of the V
domain of Alix to p6 results in conformational changes that reveal
functional sites (i.e. CHMP4 binding site) within the Bro1 domain.
The functional crosstalk between the Bro1 and V domains is also
apparent in the binding properties of the Bro1-V fragment to the
p6-deleted Gag. Bro1-V binds Gag in absence of p6 indicating
that the interaction is mediated primarily via Bro1. Disruption of
the CHMP4 binding site in Bro1-V negatively affects this
interaction, although the isolated Bro1 domain carrying the same
disruption (Bro1I212D) retains binding to Gag. This suggests that
the presence of the V domain weakens Bro1 binding to NC.
Therefore, the Bro1 domain interaction with NC is highly
influenced by the adjacent V domain, with which it has been
shown to form a tight structural unit [44]. Collectively, these
observations emphasize the functional and structural interconnec-
tion between the Bro1 and the V domains, which bind NC and p6,
respectively.
Our studies indicate that the zinc fingers within NC participate
in Bro1 interactions as their disruption decreases the ability of
Bro1 to rescue the release of HIV-1 lacking both L domain motifs
(Figure 9). However, since Bro1 retained some level of activity in
this assay, other regions in NC appear to be involved in Bro1-NC
interactions. In fact, our data identify the N-terminal portion of
NC as the functional determinant for Bro1-NC interactions, since
mutations of basic residues in this region prevented Bro1, and Alix
(data not shown), rescue of budding defects. Interestingly, the zinc
finger located within the N-terminal portion of NC is also known
to play a key role in the Bro1 domain recruitment and Alix
facilitation of HIV-1 release [60], suggesting that both the zinc
finger and basic residues in this region of NC participate in the
recruitment of the Bro1 domain of Alix. These findings identify the
N-terminal portion of NC as necessary for the recruitment of
Bro1, an essential facilitator of HIV-1 release via the LYPXnL/
Alix pathway (Figure 10A).
The role of NC in the PTAP/Tsg101 budding pathway
In the current model for HIV-1 budding, the p6-located L
domain motif PTAP is considered the primary recruitment site for
cellular factors implicated in HIV-1 budding and release. In this
study, we present evidence supporting the notion that NC
cooperates with the PTAP motif to facilitate HIV-1 release.
Interestingly, other studies show that PTAP function within HIV-1
Gag or within heterologous retroviral Gag, depends on its location
within the polyprotein [58,59], suggesting that PTAP might
require other regions in Gag to facilitate viral budding and release.
When transplanted into the retroviral Gag of RSV [58], MLV
[59]or EIAV [77], the PTAP sequence of HIV-1 p6 retains some
level of release-driving activity. Notably, in all these Gag chimeras
the PTAP motif was either transplanted as part of a sequence that
also carries the HIV-1 NC domain [59], or was placed next to the
NC domain of the ‘‘host’’ Gag [58,59,77]. In contrast, when
expressed next to the MA domain within RSV or MoMLV Gag,
the PTAP motif of HIV-1 rescues only ,30% of virus release
[58,59]. Additionally, replacement of NC with a leucine zipper
causes a severe reduction in virus release [61,62,64,78]. In fact
deletion or mutations in NC cause a severe inhibition of virus
release (Figure 9 and [61,62,63,64]), although NC-mutated Gag
proteins carry intact L domains and retain the ability to assemble
particles. Interestingly, both NC and the PTAP motif are required
for efficient budding in the context of a minimal Gag construct
[20]. Thus, within HIV-1 Gag neither NC nor the PTAP motif is
individually sufficient to mediate virus exit [10,11,61,62,63,64],
suggesting that their functions are inter-dependent.
As evidence for NC-PTAP cooperation in HIV-1 release, we
find that Broi and Bro1-V, two fragments of Alix that exhibit
dominant negative properties, potently inhibit the release of a
PTAP-dependent HIV-1. We confirmed that Broi is responsible
for the inhibition because removal of the first 202 N-terminal
residues (corresponding to Broi) of Bro1-V reverses the fragment’s
inhibitory effect on HIV-1 release. We show evidence that the
effect of Broi is specific to HIV-1 and not due to an indirect or
toxic effect on the cell, because it has no inhibitory effect on the
release of MoMLV. Additionally, deletion of the NC domain
confers resistance to Broi inhibition, demonstrating that the NC
domain of Gag is the site targeted by Broi. We therefore interpret
the Broi effect on viral release as resulting from an interference
with a NC function necessary for HIV-1 budding driven via the
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with HIV-1 budding and release from the plasma membrane as
numerous arrested budding structures decorate the cell surface. In
addition, Bro1-V causes the appearance of arrested budding
structures that carry an electron-dense filament surrounding their
budding neck, a phenotype that was previously seen following
interference with the function of ESCRT/MVB proteins
[19,20,21,51,52,53]. Interestingly, Broi over-expression causes
the formation of Class E compartments. Similarly, RNAi-
depletion of Tsg101 also leads to the formation of aberrant
endosomal compartments [79] and inhibition of HIV-1 release,
but not MoMLV [16]. Because Broi has no effect on MoMLV
release, we propose that Broi inhibition results from an
interference with the function/recruitment of components of the
cellular budding machinery that specifically cooperates with the
PTAP/Tsg101 budding pathway in HIV-1 egress. The finding
that Broi is found associated with endosomal membranes, even
though it cannot bind CHMP4 proteins suggests that this portion
of Alix associates with a cellular factor or factors that function in
endosomal compartments.
It is therefore possible that alteration of NC causes an effect
similar to that exerted by Broi (or Bro1-V) because both render
NC unavailable to recruit a host factor(s) that cooperates with
PTAP in order to facilitate virus release. In fact, we find that
mutations of basic residues in the NC domain of Gag cause a
severe decrease in HIV-1 release. Remarkably, the release of these
NC-mutated viruses is rescued by Nedd4.2s, a cellular protein that
stimulates HIV-1 release in the absence of NC and L domain
motifs PTAP and LYPXnL [75,76]. These data suggest that
mutations in NC inhibit budding by disabling the recruitment of
cellular proteins necessary for virus egress, a defect that can be
corrected by linking Gag to ESCRT proteins via a parallel
pathway (i.e Nedd.4.2s association with Gag). Interestingly,
mutations of basic residues in the first half of NC (mutant RKI)
also prevent Bro1-mediated rescue of HIV-1 release, demonstrat-
ing that this NC-mutant virus lost the ability to interact with Bro1.
These data suggest that NC may recruit the Bro1 domain of Alix
to cooperate with the PTAP motif and facilitate release. However,
Alix has been reported to be dispensable for PTAP function in
293T cells because PTAP retains activity when Alix is RNAi-
depleted from the cell [43]. These observations raise the possibility
that in 293T cells, HIV-1 may compensate for the lack of Alix by
recruiting other cellular Bro1 domain-containing proteins.
The role of NC in HIV-1 release appears to be quite
complicated, and is not limited to the recruitment of Alix, since
the release defect caused by mutations of basic residues in the C-
terminal half of NC (mutant RKII) (this study, [61,63,64]), can be
rescued by Bro1, as well as Nedd4.2s. Our findings suggest a
model in which the NC domain recruits a cellular Bro1-containing
protein (s) via its N-terminal region, and possibly an additional
cellular factor(s) through its C-terminal portion, which cooperate
with the PTAP motif in the adjacent p6 domain to facilitate HIV-1
release (Figure 10B).
In summary, our studies present evidence strongly supporting a
model in which the NC domain of Gag cooperates with L domain
motifs in the adjacent p6 domain to facilitate HIV-1 release. We
find that the NC domain of Gag is the site that interacts with the
Bro1 domain of Alix to recruit ESCRT-III CHMP4 proteins that
are necessary for HIV-1 release, thus providing a more complete
model for HIV-1 budding mediated via the LYPXnL/Alix
pathway. Additionally, we demonstrate that the NC domain of
Gag plays a key role in HIV-1 release via the PTAP/Tsg101
pathway. However, although our findings favor a model in which
NC promotes viral release by recruiting a Bro1-containing protein,
Figure 10. A model for NC cooperation with the PTAP/Tsg101 and LYPXnL/Alix budding pathways. (A) Role of NC in the LYPXnL/Alix
pathway: NC interacts with the Bro1 domain of Alix through its N-terminal basic residues and zinc fingers to recruit the essential downstream
budding machinery components, ESCRT-III and VPS4, to promote virus egress. (B) Role of NC in the PTAP/Tsg101 pathway: basic residues throughout
NC as well as zinc fingers may be required for HIV-1 budding via the PTAP motif, because they participate in the recruitment of members of the
cellular budding machinery that include a Bro1-containing protein (Bro1? or Alix) and possible additional host factor(s) (X?) that cooperate with PTAP-
bound complexes to facilitate virus release. (+) symbols represent basic residues in NC, (Zf): zinc finger.
doi:10.1371/journal.ppat.1000339.g010
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studies of the role of NC in HIV-1 budding are clearly warranted.
Materials and Methods
Proviral constructs
The wild-type (wt) full-length HIV-1 molecular clone pNL4-3
and the mutant pNL4-3 PTAP- (gift from Eric Freed) were
previously described [11,80]. The pNL4-3 DelNC/PR- and
pNL4-3 PR- plasmids (both gifts from David Ott) contain a
deletion of NC from residue 5 to 52 and/or a G75R mutation in
the protease sequence, respectively [62]. The pNL4-3 SSHS/
SSHS construct (gift from Robert Gorelick, called 2Zf- in the text)
has all cysteine (C) residues of the nucleocapsid (NC) mutated to
serine (S) [73]. The 23YP24 to 23LV24 mutation in Gag p6 was
introduced by site directed mutagenesis of pNL4-3 wt and pNL4-3
PTAP- using overlap extension PCR. The 59 primers contained
either the upstream SphI or the downstream AgeI restriction sites
and the 23LV24 mutation, conserving the underlying pol sequence.
Upstream fragments amplified from pNL4-3 PTAP- also con-
tained the PTAP to LIRL mutation. Each of the fragments was gel
purified, and amplified. The full length ‘‘LV or YP-’’ and
‘‘PTAP-/YP-’’ fragments were gel purified, digested with SphI/
AgeI and subcloned back into pNL4-3 using the LONG DNA
ligation kit (Takara Bio Inc, Madison, Wisconsin, United States) to
make pNL4-3 YP- and pNL4-3 PTAP-/YP-, respectively. The
pNL4-3 RK I and RK II plasmids were constructed using the
same overlap extension PCR method. In RK I, NC residues K3,
R7, R10, K11, K14, K20 and K26 were substituted with alanines.
RK II carries alanine substitutions of residues K26, R29, R32,
K33, K34, K38, K41, K47 and R52. The PTAP-/YP- mutation
in p6 was also introduced in pNL4-3 DelNC/PR-, pNL4-3 2Zf-,
pNL4-3 RK I and II by a similar approach, introducing the LIRL
and LV mutations simultaneously. All proviral plasmids were
grown at 30uC and their integrity was checked by HindIII
restriction digest and sequencing. Finally, the MoMLV proviral
plasmid pNCA, obtained from Steve Goff, was previously
described [81].
Expression vectors
Alix/AIP-1 cDNA was kindly donated by Heinrich Go ¨ttlinger
[20] and subcloned in pHM6 (Roche, Indianapolis, Indiana,
United States) between EcoRI/NotI for an N-terminal HA-tagged
Alix. Point mutations were introduced in Alix using the
QuickChange site-directed mutagenesis kit (Stratagene, La Jolla,
California, United States). Alix fragments Broi (residues 1–202),
Bro1 (1–367), Bro1-V (1–702), delBroV (203–702), VPRD (364–
868) and PRD (703–868) were generated by PCR amplification
from the full-length cDNA templates (wt or mutant) and
subcloning into pHM6 using the EcoRI/NotI restriction sites.
CHMP4A-DsRed2, CHMP4C-DsRed2, EGFP-VPS4A plasmids
were kindly provided by Wesley Sundquist [21]. CHMP4A and
CHMP4C genes were amplified and subcloned into p3XFLAG
(Sigma) between NotI/BglII and NotI/EcoRI respectively for N-
terminally tagged CHMP4A and C. The expression vector for N-
terminal FLAG-tagged CHMP4B was purchased from GeneCo-
poeia (Germantown, Maryland, United States). RabGAPLP/
MAP cDNA (clone Image 3027777) was purchased from Open
Biosystems and cloned into p3XFLAG plasmid between the NotI/
EcoRI sites. The Rev-independent HIV-1 Gag-EGFP construct
was kindly provided by Marilyn Resh and described previously
[82]. The pGAGwtPOL-RRE-r, pGAGDp6POL-RRE-r con-
structs, as well as the pRev1 plasmid were generous gifts from
Carol Carter and were described earlier [83]. HD-PTP (clone
Image 6579163) cDNA was purchased from Open Biosystems and
amplified to clone the full-length gene and HDBro1 fragment
(residues 1–369) in pHM6 between the HindIII/EcoRI sites.
Rhophilin-2 (clone Image 4830913) cDNA was purchased from
Open Biosystems and amplified to clone the full-length gene and
the Rho2Bro1 fragment (residues 107–507) in pHM6 between the
KpnI/NotI sites. Brox (clone image 8322687) was obtained from
Open Biosystems and subcloned in pHM6 between the EcoRI/
NotI sites. Nedd4.2s, which lacks the first 121 residues of Nedd4.2
was amplified from the full-length Nedd4.2 (clone ID 5528964
purchased from Open Biosystems) and subcloned in pHM6
between the HindIII/KpnI sites. Finally, the MBP-NC construct
was made by amplification of the whole NC region from pNL4-3
and cloned in pMAL-c2X (NEB, Ipswich, Massachusetts, United
States) between the EcoRI/BamHI sites. The MBP control plasmid
was constructed by creating a stop codon downstream of the XmnI
site of the pMAL-c2X polylinker using site directed mutagenesis.
All constructs were checked by restriction digest and sequencing.
Virus-release analysis
293T cells (2.5610
6) were seeded into T-25 flasks and
transfected the following day using Lipofectamine 2000 (Invitro-
gen) according to manufacturer instructions. For dominant
negative (DN) experiments, a pNL4.3 to DN DNA ratio ranging
from 1:5 to 1:10 was used. The amount of DNA was normalized
for each transfection with pHM6 empty plasmid. At 24 h post-
transfection, culture supernatants were filtered through 0.45 mm
syringe filters and virions were pelleted at 151,0006g for 1 h on a
20% (w/v in PBS) sucrose cushion. The cells were washed once in
PBS and lysed in NP-40 lysis buffer (1% [v/v] NP-40, 50 mM Tris
pH 8.0, 150 mM NaCl and protease inhibitor cocktail [Complete,
Roche]). Resuspended virions and cell lysis supernatants were
analyzed by SDS-PAGE on 12.5% or 15% acrylamide gels and
transferred to Immobilon-P membranes (Millipore, Billerica,
Massachusetts, Unites States). HIV-1 Gag and p24 proteins were
detected by immunoblotting using either a mouse monoclonal
anti-HIV-1 p24 (NEA-9306, NEN Life Science, Boston, Massa-
chusetts, Unites States) or an anti-HIV-1 p24 monoclonal
antibody (clone 183-H12-5C available through the NIH AIDS
Research and Reference Reagent Program). Protein expression
was detected using a monoclonal anti-HA and anti-a-tubulin
antibodies (HA-7 and DM 1A, respectively, Sigma, St. Louis,
Missouri, United States). The same protocol was used for MoMLV
release experiments. MoMLV p65Gag and p30CA were detected
using a goat anti-p30CA antibody (generous gift from Steve Goff).
HIV-1 virus release efficiency was calculated (at time 24 h post-
transfection) as the ratio of virion-associated capsid (p24) to total
cellular Gag (p55 + p24) both determined by densitometry analysis
of western blot films using ImageJ software (Rasband, W.S., NIH,
Bethesda, MD, USA, http://rsb.info.nih.gov/ij, 1997–2007). The
release efficiency of NL4-3 in presence of Alix and fragments of
Alix was compared to the release efficiency of NL4-3 alone which
was arbitrarily set at 100%.
Transmission electron microscopy (TEM)
293T cells were seeded at 6610
5/well of a 6-well plate and
transfected the following day with pNL4-3 and expression vectors
for HA-tagged full-length Alix or fragments using Lipofectamine
2000. At times 32 and 48 h post-transfection, the supernatants
were removed and the cells were fixed for 15 min at room
temperature in 2% (v/v) glutaraldehyde in 0.1 M cacodylate
buffer (pH 7.4). The cells were then rinsed in cacodylate buffer
and postfixed in 1% (v/v) osmium tetroxide in the same buffer.
The samples were subsequently rinsed again in 0.1 N sodium
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same buffer, dehydrated in graded ethanol, then infiltrated
overnight in pure epoxy resin. The wells were embedded in fresh
resin the next day and cured at 55uC. Blocks were cut from the
cured samples and mounted appropriately for ultramicrotomy.
Thin sections were stained in uranyl acetate and lead citrate and
stabilized by carbon evaporation. Images were obtained with a
Hitachi H7600 electron microscope equipped with an AMT
XL41M digital camera. Approximately 500 cells were examined
for each sample and arrested budding structures attached to the




6) were seeded into T25 flasks and transfected
the following day using Lipofectamine 2000. Forty-eight hours
post-transfection, the cells were harvested, washed twice in cold
PBS and lysed in RIPA buffer (0.5% NP-40, 50 mM Hepes
pH 7.3, 150 mM NaCl, 2 mM EDTA, 20 mM b-glycerophos-
phate, 0.1 mM Na3VO4, 1 mM NaF, 1 mM PMSF, 0.5 mM DTT
and protease inhibitor cocktail [Complete, Roche]). The lysates
were centrifuged at 16,1006g,4 uC, for 10 min and supernatants
were incubated at 4uC with EZview agarose beads covalently
attached to either anti-HA or anti-Flag mouse monoclonal
antibody (Sigma). The beads were then extensively washed in
RIPA buffer prior to 2 successive elutions with the appropriate
peptide (100 mg/ml). Immunoprecipitates and cell lysates (input
fractions) were analyzed by SDS-PAGE and immunoblotting with
anti-HA or anti-FLAG M2 antibodies (Sigma) as indicated. For
HIV-1 Gag interaction studies, the same protocol was followed
except that 293T cells (6610
6) were transfected with various
expression vectors for HA-tagged or Flag-tagged proteins along
with either pGAGPOL-RRE-r with pRev1, or pNL4-3
DelNCPR- plasmid. Immunoprecipitates and cell lysates (input
fraction) were analyzed by SDS-PAGE and immunoblotting with
anti-HA antibody (Sigma) and an HIV-positive patient serum.
Immunofluorescence microscopy
293T cells (1.8610
5) were seeded on glass coverslips in 12-well
plates and transfected the following day with the indicated
expression vectors using Lipofectamine 2000. Twenty-four hours
post-transfection, the cells were washed once in PBS, fixed for
10 min with 3.7% paraformaldehyde (EM grade, v/v in PBS),
quenched in 100 mM Glycine in PBS, permeabilized with 0.5% (v/
v inPBS) TritonX-100 (Sigma) for2 minandblocked in1%(v/vin
PBS)BSAfor 30 min. Primary antibodyanti-HA (SigmaHA-7) was
applied at 1:5000 in 1% BSA for 1 h followed by an Alexa 633
conjugated secondary anti-mouse antibody (Invitrogen). F-actin was
stained with Alexa 568 conjugated Phalloidin and nuclei were
counterstained with DAPI 1 mg/ml. Coverslips were mounted with
ProLong Gold (Invitrogen) on microscope glass slides and allowed
to cure overnight. Sequential Z-sections (about 0.25 mm each) were
obtained by confocal microscopy (Leica SP5 confocal microscope,
Leica Microsystems, Exton, PA, United States). Raw data were
deconvolved with Huygens Essentials software (version 3.1,
Scientific Volume Imaging BV, Hilversum, The Netherlands)
reconstructed in 3-D and analyzed with Imaris software (version
6.0, Bitplane AG, Zurich, Switzerland) for colocalization statistics.
In vitro pull-down assay
E.coli TB1 (JM83 hsdR) cells were transformed with the pMAL
control and NC plasmids, grown to exponential phase and
induced with IPTG for 3 to 4 h. Cells were harvested and lysed in
column buffer (20 mM Tris-HCl pH 7.5, 200 mM NaCl, 1 mM
DTT, 1 mM PMSF and protease inhibitor cocktail) by sonication.
Lysates were cleared by centrifugation and were incubated with
amylose resin to allow binding. The resin was washed extensively
with column buffer and RIPA buffer. In parallel, 293T cells were
transfected with expression vectors for HA-tagged fragments of
Alix as described in the Immunoprecipitation assay section. At
48 h post-transfection 293T cells were lysed in RIPA buffer and
cleared lysates were incubated with immobilized MBP control or
MBP-NC on resin. After extensive washes in RIPA buffer, the
resin was boiled in sample buffer and analyzed by SDS-PAGE and
western blot using anti-HA antibody or Coomassie blue staining.
Accession numbers (GenBank) of genes used in this
study
Alix (NM_013374), Bro1p (Yeast U37364), Brox (BC113635),
CHMP4A (BC113533), CHMP4B (BC033859), CHMP4C
(BC014321), HD-PTP (BC089042), Nedd4.2 (BC032597), Rab-
GAPLP or MAP (NM_015705), Rhophilin-2 (BC036447) and
VPS4A (BC047932).
Supporting Information
Figure S1 Alix over-expression interferes with HIV-1 budding.
(A) Titration of HA-Alix used in the rescue of HIV-1 PTAP- and
inhibition of wt HIV-1. 293T cells were transfected with either
pNL4-3 PTAP- (lanes 1–5) or pNL4-3 wt (lanes 6–9) in absence
(lanes 1 & 6) or presence of 0.15 mg (lane 2), 0.7 mg (lanes 3 & 7),
1.5 mg (lanes 4 & 8) and 3 mg (lanes 5 & 9) of HA-Alix per million
cells. Pelleted virions and cell lysates were analyzed by SDS-PAGE
and western blot using the indicated antibodies. Note that the
optimal rescue of HIV-1 PTAP- was obtained with 0.6 mg of HA-
Alix (lane 3) whereas 3 mg of HA-Alix failed to rescue the release of
HIV-1 PTAP- (lane 5) and inhibited wt HIV-1 (lane 9). (B)
Transmission Electron Microscopy (TEM) images of thin-sectioned
293T cells transfected with the HIV-1 BH-10 molecular clone,
alone (a) or with Alix (b–f) showing arrested budding particles.
Found at: doi:10.1371/journal.ppat.1000339.s001 (2.92 MB PDF)
Figure S2 Broi and Bro1-V over-expression interfere with HIV-1
budding. Electron micrographs of 293T cells co-transfected with
pNL4-3wtandHA-Broi(A)orBro1-V(B)showingarrestedbudding
particles.Arrows indicate structures arrested at latebudding steps.In
the inset labeled (b), an arrested particle carrying an electron-dense
‘‘ring-like’’ structure (arrows) is shown at a higher magnification.
Found at: doi:10.1371/journal.ppat.1000339.s002 (3.01 MB PDF)
Figure S3 Broi does not bind CHMP4 isoforms. 293T cells were
co-transfected with HA-Alix or Alix fragments and either FLAG-
tagged CHMP4A (panel A), CHMP4B (panel B), CHMP4C (panel
C), or MAP/RabGAPLP (panel D). Alix and fragments were
captured from cell lysates using anti-HA antibody-conjugated
beads. All fractions, input and immunoprecipitated, were analyzed
by SDS-PAGE and western blot using anti-HA and anti-Flag
antibodies as indicated.
Found at: doi:10.1371/journal.ppat.1000339.s003 (2.51 MB PDF)
Figure S4 Alignment of protein sequences of Bro1 domains
from five different Bro1-containing proteins. Bro1 domains from
the human Alix, HD-PTP, Rhophilin-2, and Brox as well as the
yeast Bro1p protein sequences were aligned using the Align X
program of the Vector NTI suite. Conserved residues are
highlighted in colors.
Found at: doi:10.1371/journal.ppat.1000339.s004 (0.14 MB PDF)
Figure S5 Bro1 domains of HD-PTP and Rhophilin-2 interact
with Gag, but only Alix Bro1 promotes viral budding. (A)
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PTP, and Rhophilin-2 used in this experiment. PRD: Proline Rich
Domain, PTP: Protein Tyrosine Phosphatase, PEST: Proline-
glutamic acid (E)-Serine-Threonin rich region, RB: Rho Binding
domain and PDZ: PS.D.-95, Disc-large, ZO-1 domain. (B) Bro1
domains of Alix, HD-PTP, and Rhophilin-2 co-immunoprecipi-
tate with HIV-1 Gag. 293T cells expressing Gag-Pol alone or with
HA-Bro1, HA-Bro1I212D, HA-HDBro1, and HA-RhoBro1 were
lysed in RIPA buffer and incubated with anti-HA antibody-
conjugated beads. Both input and immunoprecipitated complexes
were analyzed by SDS-PAGE and western blot using indicated
antibodies. (C) Over-expression of only the Alix Bro1 domain,
rescued the release of the NL4-3 PTAP-/YP- virus. 293T cells
were transfected with either pNL4-3 PTAP-/YP- plasmid alone or
with increasing amounts of HA-Bro1, HA-HDBro1, or HA-
RhoBro1. Pelleted virions and cell lysates were analyzed by SDS-
PAGE and western blot using the indicated antibodies. (D) Over-
expression of HA-Bro1, but not HA-HDBro1, stimulates HIV-1
release. 293T cells were transfected with either wt pNL4-3 plasmid
alone or with increasing amounts of HA-Bro1 or HA-HDBro1.
Pelleted virions and cell lysates were analyzed by SDS-PAGE and
western blot using the indicated antibodies.
Found at: doi:10.1371/journal.ppat.1000339.s005 (5.82 MB PDF)
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